ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition

ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition

Story continues below

On October27, 2017, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September30, 2017. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit No.



Press Release dated October 27, 2017 (furnished to Item 2.02).

AbbVie Inc. Exhibit
EX-99.1 2 abbv-20170930xexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 PRESS RELEASE AbbVie Reports Third-Quarter 2017 Financial Results  •Reports Third-Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41,…
To view the full exhibit click here


AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

An ad to help with our costs